Evidence map›Paper›PMID 24841413›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2014

Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging.

Thomas de Perrot, Olivier Rager, Max Scheffler, Martin Lord, Marc Pusztaszeri, Christophe Iselin, Osman Ratib, Jean-Paul Vallee

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  2. Clinical PET/MR.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Current Status of Hybrid PET/MRI in Oncologic Imaging.AJR. American journal of roentgenology · 2016
    Review
  10. Prostate cancer recurrence: can PSA guide imaging?European journal of nuclear medicine and molecular imaging · 2015
    Article
  11. Review
  12. PET/MRI in Oncological Imaging: State of the Art.Diagnostics (Basel, Switzerland) · 2015
    Review
  13. Imaging biomarkers in prostate cancer: role of PET/CT and MRI.European journal of nuclear medicine and molecular imaging · 2015
    Review
  14. Excellence is the Enemy of Good.World journal of nuclear medicine · 2014
    Article
  15. Article
  16. Molecular Imaging of Prostate Cancer.Radiographics : a review publication of the Radiological Society of North America, Inc
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thomas de PerrotDivision of Radiology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Genève 14, Switzerland, thomas.deperrot@hcuge.ch.
Olivier Rager
Max Scheffler
Martin Lord
Marc Pusztaszeri
Christophe Iselin
Osman Ratib
Jean-Paul Vallee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report the first results of hybrid (18)F-fluorocholine PET/MRI imaging for the detection of prostate cancer.

methodsThis analysis included 26 consecutive patients scheduled for prostate PET/MRI before radical prostatectomy. The examinations were performed on a hybrid whole-body PET/MRI scanner. The MR acquisitions which included T2-weighted, diffusion-weighted and dynamic contrast-enhanced sequences were followed during the same session by whole-body PET scans. Parametric maps were constructed to measure normalized T2-weighted intensity (nT2), apparent diffusion coefficient (ADC), volume transfer constant (K (trans)), extravascular extracellular volume fraction (v e) and standardized uptake values (SUV). With pathology as the gold standard, ROC curves were calculated using logistic regression for each parameter and for the best combination with and without PET to obtain a MR model versus a PETMR model.

resultsOf the 26 patients initially selected, 3 were excluded due to absence of an endorectal coil (2 patients) or prosthesis artefacts (1 patient). In the whole prostate, the area under the curve (AUC) for SUVmax, ADC, nT2, K (trans) and v e were 0.762, 0.756, 0.685, 0.611 and 0.529 with a best threshold at 3.044 for SUVmax and 1.075 × 10(-3) mm(2)/s for ADC. The anatomical distinction between the transition zone and the peripheral zone showed the potential of the adjunctive use of PET. In the peripheral zone, the AUC of 0.893 for the PETMR model was significantly greater (p = 0.0402) than the AUC of 0.84 for the MR model only. In the whole prostate, no relevant correlation was observed between ADC and SUVmax. The SUVmax was not affected by the Gleason score.

conclusionThe performance of a hybrid whole-body (18)F-fluorocholine PET/MRI scan in the same session combined with a prostatic MR examination did not interfere with the diagnostic accuracy of the MR sequences. The registration of the PET data and the T2 anatomical MR sequence data allowed precise localization of hypermetabolic foci in the prostate. While in the transition zone the adenomatous hyperplasia interfered with cancer detection by PET, the quantitative analysis tool performed well for cancer detection in the peripheral zone.

Indexed as

Magnetic Resonance ImagingMultimodal ImagingPositron-Emission TomographyAgedCholineFeasibility StudiesHumansMaleMiddle AgedMultivariate AnalysisProstatic NeoplasmsROC CurveCholinefluorocholine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.